GG1前列腺癌根治术病理升级:确证检测对主动监测选择的意义
结果显示GG1患者升级至≥GG2和不良病理常见,确证检测结果不令人安心者不良病理比例更高(35% vs 18%,P=0.017),提示早期确证检测可能改善风险分层和主动监测患者选择。
要点
- GG1前列腺癌根治术后升级至≥GG2和不良病理常见。
- 确证检测结果不令人安心者不良病理比例更高(35% vs 18%)。
- 早期确证检测可能帮助识别更具侵袭性疾病并改善主动监测选择。
核心结论
- GG1前列腺癌患者根治术后病理升级和不良病理常见,早期确证检测可能有助于识别更具侵袭性疾病并改善主动监测患者选择。
主要发现
- 在1966例诊断时GG1患者中,升级至≥GG2和不良病理的总发生率分别为40%和10%。
- 极低危和低危患者升级至≥GG2的发生率分别为40%和59%(P<0.001),不良病理发生率分别为10%和17%(P=0.003)。
- 按阳性穿刺针数分层,升级至≥GG2的发生率为49%至67%,不良病理发生率为16%至23%。
- 年龄≥70岁患者较<70岁患者不良病理更多。
- 确证检测结果不令人安心者较令人安心者不良病理可能性更高(35% vs 18%,P=0.017)。
临床怎么用
- 对考虑主动监测的GG1前列腺癌患者,可早期行确证检测以辅助识别更具侵袭性疾病并改善风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the association between National Comprehensive Cancer Network (NCCN) risk, number of positive biopsy cores, age, and early confirmatory test results on pathological upgrading at radical prostatectomy (RP), in order to better understand whether early confirmatory testing and better risk stratification are necessary for all men with Grade Group (GG) 1 cancers who are considering active surveillance (AS). PATIENTS AND METHODS: We identified men in Michigan initially diagnosed with GG1 prostate cancer, from January 2012 to November 2017, who had a RP within 1 year of diagnosis. Our endpoints were: (i) ≥GG2 cancer at RP and (ii) adverse pathology (≥GG3 and/or ≥pT3a). We compared upgrading according to NCCN risk, number of positive biopsy cores, and age. Last, we examined if confirmatory test results were associated with upgrading or adverse pathology at RP. RESULTS: Amongst 1966 patients with GG1 cancer at diagnosis, the rates of upgrading to ≥GG2 and adverse pathology were 40% and 59% (P < 0.001), and 10% and 17% (P = 0.003) for patients with very-low- and low-risk cancers, respectively. Upgrading by volume ranged from 49% to 67% for ≥GG2, and 16% to 23% for adverse pathology. Generally, more patients aged ≥70 vs <70 years had adverse pathology. Unreassuring confirmatory test results had a higher likelihood of adverse pathology than reassuring tests (35% vs 18%, P = 0.017). CONCLUSIONS: Upgrading and adverse pathology are common amongst patients initially diagnosed with GG1 prostate cancer. Early use of confirmatory testing may facilitate the identification of patients with more aggressive disease ensuring improved risk classification and safer selection of patients for AS.
引用
- Kaye DR, Qi J, Morgan TM, et al. Pathological upgrading at radical prostatectomy for patients with Grade Group 1 prostate cancer: implications of confirmatory testing for patients considering active surveillance. BJU Int. 2018. PMID: 30248225. doi:10.1111/bju.14554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。